Freenome, a biotechnology company pioneering an early cancer detection platform, today announced the appointment of Aaron ...

The partners plan to build evidence packages that standardize comprehensive genomic profiling and other molecular testing ...

Researchers from Mass General Brigham , Harvard Medical School and Duke University School of Medicine have identified nearly ...

Aaron joins Freenome most recently from REALM IDx, Inc., where he served as CEO and president for nearly four years, overseeing its subsidiaries Ambry Genetics, Invicro and Konica Minolta REALM-Japan.

Researchers from Mass General Brigham, Harvard Medical School and Duke University School of Medicine have identified nearly 300 genetic disorders that can be treated before or immediately after a baby ...

Both TEM and DOCS are technology-intensive healthcare companies leveraging artificial intelligence to enhance their platforms ...

The February 2025 acquisition of Ambry Genetics further expanded its genomics capabilities with a West Coast lab and enhanced inherited risk testing. Additionally, a five-year extension with ...

In February 2025, Tempus AI, Inc. (NASDAQ:TEM) completed the acquisition of Ambry Genetics, enhancing its capabilities in genetic testing and data services. Tempus’s stock has experienced ...

Tempus "increased" its 2025 revenue guidance from $1.23 billion to $1.24 billion (for the consolidated Tempus and Ambry Genetics business), with adjusted EBITDA of “approximately $5 million.” ...